Cemdisiran

• UNSPSC Description:

  Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.

• Target Antigen:

  Complement System; Small Interfering RNA (siRNA)

• Type:

  Oligonucleotides

• Related Pathways:

  Epigenetics;Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/cemdisiran.html

• Solubility:

  H2O : ≥ 20 mg/mL

• Smiles:

  [Cemdisiran]

• Molecular Weight:

  16782.53

• References & Citations:

  [1]Badri P, Jiang X, Borodovsky A, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365-378.|[2]Prajakta Badri, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365-378.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  Phase 3

• CAS Number:

  1639264-46-2